Inherited Determinants of Pharmacokinetic Variability in Anti-Ageing Pharmacotherapy: A Structured Narrative Review of Chromosomal Architecture, Transporter Pharmacogenomics, Drug–Drug Interaction Networks, and Population Genetic Diversity for Metformin and Sirolimus
SN Comprehensive Clinical Medicine · 07.11.2026 · 8 (1)
DOI: 10.1007/s42399-026-02875-x ↗Kurz gefasst
Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 07.11.2026. Verfasst von Karikalachsozhan Prakash Raj und 1 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
The therapeutic application of metformin and sirolimus (rapamycin) in longevity-oriented medicine is complicated by substantial interindividual pharmacokinetic variability arising from inherited differences in drug-metabolising enzymes and membrane transporters. Metformin disposition is governed by a coordinated transporter network involving OCT1 (SLC22A1), OCT2 (SLC22A2), MATE1 (SLC47A1), and MATE2-K (SLC47A2), which collectively regulate hepatic uptake and renal elimination. Sirolimus exposure is influenced by CYP3A-mediated metabolism, P-glycoprotein transport, drug–drug interactions, and patient-specific factors, while CYP3A5 expression status (rs776746) may contribute to interindividual pharmacokinetic variability. This structured narrative review critically synthesizes pharmacokinetic, pharmacogenomic, population genetics, and drug–drug interaction evidence to evaluate the mechanistic and clinical basis for genotype-guided dosing of metformin and sirolimus across diverse populations. Targeted literature searches of PubMed/MEDLINE, Embase, and the Cochrane Library informed a structured narrative synthesis of relevant publications from January 1990 to December 2024. Evidence was evaluated according to study design, pharmacokinetic relevance, clinical applicability, and methodological limitations. Additional evidence was obtained from FDA prescribing information, CPIC guidance documents, and the PharmGKB database. Eligible studies included clinical pharmacokinetic investigations, population genetics studies, physiologically based pharmacokinetic (PBPK) models, and pharmacogenomic cohort analyses. CYP3A5 genotype was associated with variability in sirolimus pharmacokinetics, with the magnitude and consistency of genotype-associated differences varying across clinical investigations and pharmacokinetic models. CYP3A5*1 allele frequency varied markedly across populations, ranging from 5 to 15% in Europeans to 70–85% in Sub-Saharan Africans, although these population-level genetic differences do not establish ancestry-specific sirolimus dose requirements. For metformin, selected reduced-function OCT1 coding variants were associated with increased systemic exposure in a small pharmacokinetic investigation, whereas a separate steady-state study did not identify a statistically significant genotype association. These findings should be distinguished from the inconsistent clinical-response evidence for the intronic SLC22A1 rs622342 polymorphism. Differences in study design, genotype classification, and participant characteristics may contribute to these inconsistent findings. Strong CYP3A4/P-glycoprotein inhibitors and inducers substantially modified sirolimus exposure, indicating that pharmacogenetic and drug–drug interaction effects must be interpreted together within integrated dosing frameworks. Current evidence supports further investigation of CYP3A5-informed dosing strategies; however, prospective clinical studies are required to establish their safety, clinical utility, and effectiveness. OCT1 genotyping may contribute to understanding variability in metformin response, although its routine clinical utility remains insufficiently established. Although prospective longevity-specific clinical trials remain limited, existing pharmacogenomic and pharmacokinetic evidence provides a scientifically grounded framework for precision dosing and highlights pharmacogenetic health equity as an important translational priority.
Zitieren
APA
Raj, K. P., & Sabarees, G. (2026). Inherited Determinants of Pharmacokinetic Variability in Anti-Ageing Pharmacotherapy: A Structured Narrative Review of Chromosomal Architecture, Transporter Pharmacogenomics, Drug–Drug Interaction Networks, and Population Genetic Diversity for Metformin and Sirolimus. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02875-x
Vancouver
Raj KP, Sabarees G. Inherited Determinants of Pharmacokinetic Variability in Anti-Ageing Pharmacotherapy: A Structured Narrative Review of Chromosomal Architecture, Transporter Pharmacogenomics, Drug–Drug Interaction Networks, and Population Genetic Diversity for Metformin and Sirolimus. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02875-x
BibTeX
@article{Raj2026,
author = {Raj, Karikalachsozhan Prakash and Sabarees, Govindaraj},
title = {Inherited Determinants of Pharmacokinetic Variability in Anti-Ageing Pharmacotherapy: A Structured Narrative Review of Chromosomal Architecture, Transporter Pharmacogenomics, Drug–Drug Interaction Networks, and Population Genetic Diversity for Metformin and Sirolimus},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02875-x}
}
EUVIMED